Inmode Ltd
NASDAQ:INMD
Intrinsic Value
InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. [ Read More ]
The intrinsic value of one INMD stock under the Base Case scenario is 31.36 USD. Compared to the current market price of 17.34 USD, Inmode Ltd is Undervalued by 45%.
Valuation Backtest
Inmode Ltd
Run backtest to discover the historical profit from buying and selling INMD stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Inmode Ltd
Current Assets | 845.3m |
Cash & Short-Term Investments | 741.6m |
Receivables | 58.6m |
Other Current Assets | 45.1m |
Non-Current Assets | 18m |
Long-Term Investments | 700k |
PP&E | 12.1m |
Other Non-Current Assets | 5.2m |
Current Liabilities | 64.1m |
Accounts Payable | 14m |
Other Current Liabilities | 50.2m |
Non-Current Liabilities | 11.8m |
Other Non-Current Liabilities | 11.8m |
Earnings Waterfall
Inmode Ltd
Revenue
|
492m
USD
|
Cost of Revenue
|
-80.7m
USD
|
Gross Profit
|
411.3m
USD
|
Operating Expenses
|
-215.7m
USD
|
Operating Income
|
195.7m
USD
|
Other Expenses
|
2.3m
USD
|
Net Income
|
197.9m
USD
|
Free Cash Flow Analysis
Inmode Ltd
What is Free Cash Flow?
INMD Profitability Score
Profitability Due Diligence
Inmode Ltd's profitability score is 82/100. The higher the profitability score, the more profitable the company is.
Score
Inmode Ltd's profitability score is 82/100. The higher the profitability score, the more profitable the company is.
INMD Solvency Score
Solvency Due Diligence
Inmode Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Inmode Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
INMD Price Targets Summary
Inmode Ltd
According to Wall Street analysts, the average 1-year price target for INMD is 28.15 USD with a low forecast of 21.21 USD and a high forecast of 34.65 USD.
Shareholder Return
INMD Price
Inmode Ltd
Average Annual Return | 84.94% |
Standard Deviation of Annual Returns | 115.79% |
Max Drawdown | -82% |
Market Capitalization | 1.5B USD |
Shares Outstanding | 85 835 000 |
Percentage of Shares Shorted | 7.44% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. The company designs, develops, manufactures and commercializes energy-based, minimally-invasive surgical aesthetic and medical treatment solutions. The Company’s proprietary technologies are used by physicians to remodel subdermal adipose, or fatty, tissue in a variety of procedures including fat reduction with simultaneous skin tightening, face and body contouring and ablative skin rejuvenation treatments. Its products target a wide array of procedures including simultaneous fat killing and skin tightening, permanent hair reduction, skin appearance and texture, among others. The Company’s products may be used on a variety of body parts, including the face, neck, abdomen, upper arms, thighs and intimate feminine regions. The company owns six product platforms: BodyTite, Optimas, Votiva, Contoura, Triton and EmbraceRF. All are market and sell traditionally to plastic and facial surgeons, aesthetic surgeons and dermatologists, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one INMD stock under the Base Case scenario is 31.36 USD.
Compared to the current market price of 17.34 USD, Inmode Ltd is Undervalued by 45%.